JLJing Liu

Jing Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jing Liu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Yun Guan

    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD, United States

    5 shared publications
  • Xiang Cui

    China Academy Of Chinese Medical Sciences

    4 shared publications
  • Ankit Uniyal

    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA

    2 shared publications
  • Chi Zhang

    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

    2 shared publications
  • Jieru Wan

    Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, 21205, USA

    2 shared publications
  • Qian Xu

    Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA

    2 shared publications

Latest Publications

  • Targeting A3 adenosine receptor signaling to enhance analgesia in nonresponders to spinal cord stimulation in male nerve-injured rats

    by Zhaoli Luo, Jing Liu, Xiang Cui, Ankit Uniyal, Jieru Wan, Qin Zheng, Yun Guan

    Spinal cord stimulation (SCS) is a clinically approved therapy for neuropathic pain (NP), yet a substantial subset of patients fails to respond or shows minimal efficacy, so-called nonresponders. It remains unclear how to resolve this SCS nonresponsiveness. Using a NP model induced by tibial-sparing nerve injury (SNI-t) in male rats, we investigated whether targeting the A3 adenosine receptor (A3AR), which is enriched in microglial cells, could convert nonresponders into responders. The dose–response relationship of 2-Cl-IB-MECA (a highly selective A3AR agonist) to inhibit mechanical hypersensitivity in male SNI-t rats after intraperitoneal injection was first established by measuring the paw withdrawal thresholds. Responders and nonresponders were classified based on the degree of reduction in mechanical hypersensitivity induced by conventional SCS (50 Hz, 0.2 milliseconds, 80% motor threshold, 30 minutes). A subtherapeutic dose of 2-Cl-IB-MECA (0.3 mg/kg, intraperitoneal) was subsequently combined with either acute or repeated SCS in nonresponders. Repeated SCS reduced microglial activation but produced limited analgesia in nonresponders. Subtherapeutic-dose 2-Cl-IB-MECA by itself induced minimal pain inhibition; however, when combined with SCS, it restored analgesic responses to both acute and repeated SCS. Notably, the pain reduction from repeated SCS was accompanied by a shift toward an anti-inflammatory microglial phenotype. These findings suggest that persistent microglial activation in male SNI-t rats may contribute to SCS nonresponsiveness, and that engaging A3AR signaling represents a promising strategy to convert nonresponders into SCS responders in NP conditions.

  • In vivo GCaMP imaging reveals distinct subsets of dorsal root ganglion neurons driving spontaneous pain after nerve injury in mice

    by Leo C. Guan, Jing Liu, Zhaoli Luo, Michael Jiang, Jun-Ming Zhang, Qin Zheng

    Spontaneous pain is a hallmark and debilitating feature of neuropathic pain, yet the mechanisms driving spontaneous pain remain poorly understood. Although abnormal spontaneous activity (SA) in primary sensory neurons has been observed after nerve injury, it remains unclear how such activity is organized across neuronal populations within the dorsal root ganglion (DRG) and how it relates to different pain components. Here, we used large-scale in vivo calcium imaging to examine spontaneous and stimulus-evoked activity in lumbar DRG neurons after spared-nerve injury (SNI). Spared-nerve injury significantly increased the incidence of single-neuron SA in DRG neurons. By combining functional imaging with retrograde labeling, we found that this activity arose not only from injured afferents (51.8%) but also from a substantial population of spared neurons (48.2%) within the same ganglion. Among spared neurons exhibiting spontaneous activity, nearly half (48.4%) showed no detectable responses to a broad panel of mechanical and thermal stimuli under our recording conditions, whereas most responsive neurons retained modality selectivity. Importantly, the incidence of single-neuron SA was positively associated with spontaneous pain-like behavior, but not with mechanical hypersensitivity, after SNI, supporting a direct link between SA of DRG neurons and spontaneous neuropathic pain. Together, these findings show that SA in the DRG is organized across both anatomical and functional dimensions, providing a framework for understanding how abnormal peripheral neuronal activity relates to spontaneous neuropathic pain.


  • Open Access

    Mast cell-specific receptor MrgprB2 selectively mediates oxaliplatin-induced neuropathic pain

    by Leo C. Guan, Zhaoli Luo, Ruchita Kothari, Meilian Liu, Jieru Wan, Ankit Uniyal, Annie Y. Guan, Qing Lin, Xinzhong Dong, Jing Liu

    Background: Chemotherapy-induced peripheral neuropathy (CIPN) causes debilitating pain that limits anticancer treatment, yet effective therapies remain limited. Mast cells (MCs) regulate neuroimmune signaling implicated in CIPN, but their receptor-specific contributions remain poorly understood. In mice, oxaliplatin and paclitaxel produce robust mechanical and cold hypersensitivities that mirror CIPN pain. Mas -related G-protein-coupled receptor B2 (MrgprB2) and its human orthologue MrgprX2 are MC-restricted receptors that mediate non-IgE-mediated activation. However, whether MrgprB2 signaling differently contributes to oxaliplatin- versus paclitaxel-induced CIPN pain remains unclear. Methods: We employed a comparative mechanistic approach using wild-type (WT) and MrgprB2 knockout (KO) mice to define receptor-specific contributions to oxaliplatin- versus paclitaxel-induced CIPN pain. Behavioral assessments of mechanical and cold hypersensitivity were integrated with histological profiling of MC recruitment and mediator profiles. Genetic findings were validated pharmacologically with osthole, a natural MrgprB2/X2 antagonist. Results: Both oxaliplatin and paclitaxel induced cutaneous MC accumulation in the hindpaw of WT mice, but they triggered distinct MC mediator-release profiles in vivo: oxaliplatin preferentially elevated tryptase, while paclitaxel was associated with greater histamine enrichment. Yet, neither drug directly activate MCs in vitro, as indicated by unchanged β-hexosaminidase release and calcium signaling. Importantly, MrgprB2 KO selectively attenuated oxaliplatin-induced tryptase upregulation and mechanical and cold hypersensitivity in vivo, without affecting paclitaxel-induced histamine changes or pain behavior. Consistently, with these genetic results, osthole selectively attenuated oxaliplatin-induced pain, but not paclitaxel-induced pain in WT mice. Conclusions: These findings support a mechanistic dichotomy in CIPN pain, indicating that MrgprB2 contributes selectively to oxaliplatin-induced, but not paclitaxel-induced, CIPN in mice. More broadly, they suggest that CIPN involves mechanistically distinct neuroimmune states depending on the chemotherapeutic class and highlight MrgprB2/X2 as a drug class-selective target for platinum-induced CIPN pain treatment.

  • An orally bioavailable MrgprX1-positive allosteric modulator alleviates certain neuropathic pain–related behaviors in humanized mice

    by Ankit Uniyal, Niyada Hin, Chi Zhang, Qian Xu, Qian Huang, Ilyas Berhane, Ajit G. Thomas, John Maragakis, Sadakatali Gori, Jing Liu, et al.

    The human Mas -related G protein–coupled receptor X1 (MrgprX1) represents a promising nonopioid analgesic target because of its selective expression in primary nociceptive sensory neurons. Positive allosteric modulators (PAMs) promote receptor signaling, depending on the availability of endogenous ligands, offering physiological selectivity over orthosteric agonists. We developed an orally bioavailable MrgprX1 PAM, 6-tert-butyl-5-(4-chlorophenyl)-4-(2-fluoro-6-(trifluoromethoxy)phenoxy)thieno[2,3-d]pyrimidine (BCFTP). BCFTP selectively potentiated the functional response of MrgprX1 in HEK293 cells, was metabolically stable, and demonstrated a favorable in vitro safety profile. BCFTP was orally bioavailable and distributed into the spinal cords of wild-type mice. BAM22, an endogenous ligand for MrgprX1, was up-regulated in the spinal cord after nerve injury in both wild-type and humanized MrgprX1 mice and was expressed in peptidergic and nonpeptidergic dorsal root ganglion neurons. Oral administration of BCFTP dose-dependently inhibited heat hyperalgesia and spontaneous pain-like behavior but not mechanical hypersensitivity after sciatic chronic constrictive injury (CCI) in MrgprX1 mice. BCFTP did not have analgesic effects in Mrgpr cluster knockout (Mrgpr −/− ) mice, indicating that the analgesic effects in MrgprX1 mice were MrgprX1 dependent. BCFTP enhanced BAM8-22–induced, MrgprX1-mediated reduction of C-fiber eEPSC amplitudes in spinal lamina II neurons, indicating inhibition of spinal nociceptive synaptic transmission. BCFTP did not induce tolerance or side effects, such as itch, sedation, and motor incoordination, and had no rewarding properties. The mRNAs encoding MrgprX1 and μ-opioid receptors were colocalized in human DRG neurons, and BCFTP synergistically enhanced morphine analgesia in CCI MrgprX1 mice. Our research suggests an approach for developing safer, orally bioavailable MrgprX1 PAM as a nonopioid therapy for neuropathic pain.


  • Open Access

    HC-HA/PTX3 from Human Amniotic Membrane Induced Differential Gene Expressions in DRG Neurons: Insights into the Modulation of Pain

    by Shao-Qiu He, Chi Zhang, Xue-Wei Wang, Qian Huang, Jing Liu, Qing Lin, Hua He, Da-Zhi Yang, Scheffer C. Tseng, Yun Guan

    Background: The biologics derived from human amniotic membranes (AMs) demonstrate potential pain-inhibitory effects in clinical settings. However, the molecular basis underlying this therapeutic effect remains elusive. HC-HA/PTX3 is a unique water-soluble regenerative matrix that is purified from human AMs. We examined whether HC-HA/PTX3 can modulate the gene networks and transcriptional signatures in the dorsal root ganglia (DRG) neurons transmitting peripheral sensory inputs to the spinal cord. Methods: We conducted bulk RNA-sequencing (RNA-seq) of mouse DRG neurons after treating them with HC-HA/PTX3 (15 µg/mL) for 10 min and 24 h in culture. Differential gene expression analysis was performed using the limma package, and Gene Ontology (GO) and protein–protein interaction (PPI) analyses were conducted to identify the networks of pain-related genes. Western blotting and in vitro calcium imaging were used to examine the protein levels and signaling of pro-opiomelanocortin (POMC) in DRG neurons. Results: Compared to the vehicle-treated group, 24 h treatment with HC-HA/PTX3 induced 2047 differentially expressed genes (DEGs), which were centered on the ATPase activity, receptor–ligand activity, and extracellular matrix pathways. Importantly, PPI analysis revealed that over 50 of these DEGs are closely related to pain and analgesia. Notably, HC-HA/PTX3 increased the expression and signaling pathway of POMC, which may affect opioid analgesia. Conclusions: HC-HA/PTX3 induced profound changes in the gene expression in DRG neurons, centered around various neurochemical mechanisms associated with pain modulation. Our findings suggest that HC-HA/PTX3 may be an important biological active component in human AMs that partly underlies its pain inhibitory effect, presenting a new strategy for pain treatment.


  • Enhancing spinal cord stimulation-induced pain inhibition by augmenting endogenous adenosine signalling after nerve injury in rats

    by Xiang Cui, Jing Liu, Ankit Uniyal, Qian Xu, Chi Zhang, Guangwu Zhu, Fei Yang, Eellan Sivanesan, Bengt Linderoth, Srinivasa N. Raja, et al.


  • Open Access

    BzATP Activates Satellite Glial Cells and Increases the Excitability of Dorsal Root Ganglia Neurons In Vivo

    by Zhiyong Chen, Chi Zhang, Xiaodan Song, Xiang Cui, Jing Liu, Neil C. Ford, Shaoqiu He, Guangwu Zhu, Xinzhong Dong, Menachem Hanani, et al.

    The purinergic system plays an important role in pain transmission. Recent studies have suggested that activation of P2-purinergic receptors (P2Rs) may be involved in neuron-satellite glial cell (SGC) interactions in the dorsal root ganglia (DRG), but the details remain unclear. In DRG, P2X7R is selectively expressed in SGCs, which closely surround neurons, and is highly sensitive to 3’-O-(4-Benzoyl) benzoyl-ATP (BzATP). Using calcium imaging in intact mice to survey a large number of DRG neurons and SGCs, we examined how intra-ganglionic purinergic signaling initiated by BzATP affects neuronal activities in vivo. We developed GFAP-GCaMP6s and Pirt-GCaMP6s mice to express the genetically encoded calcium indicator GGCaM6s in SGCs and DRG neurons, respectively. The application of BzATP to the ganglion induced concentration-dependent activation of SGCs in GFAP-GCaMP6s mice. In Pirt-GCaMP6s mice, BzATP initially activated more large-size neurons than small-size ones. Both glial and neuronal responses to BzATP were blocked by A438079, a P2X7R-selective antagonist. Moreover, blockers to pannexin1 channels (probenecid) and P2X3R (A317491) also reduced the actions of BzATP, suggesting that P2X7R stimulation may induce the opening of pannexin1 channels, leading to paracrine ATP release, which could further excite neurons by acting on P2X3Rs. Importantly, BzATP increased the responses of small-size DRG neurons and wide-dynamic range spinal neurons to subsequent peripheral stimuli. Our findings suggest that intra-ganglionic purinergic signaling initiated by P2X7R activation could trigger SGC-neuron interaction in vivo and increase DRG neuron excitability.